Genscript Biotech (HK:1548) has released an update.
Genscript Biotech Corporation reports robust growth for the first half of 2024, with a significant revenue increase of 43.5% to US$561.4 million, driven by a 156% surge in its cell therapy business. Despite this, the company’s non-cell therapy segment saw a slight revenue decline. Overall, the company’s losses narrowed, with an adjusted net loss of US$69.0 million, improving from the previous period’s US$162.0 million loss.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
